NCT00819546 2026-03-25RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDSDana-Farber Cancer InstitutePhase 1 Active not recruiting29 enrolled
NCT02115295 2025-11-06Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaM.D. Anderson Cancer CenterPhase 2 Recruiting508 enrolled